Matches in SemOpenAlex for { <https://semopenalex.org/work/W2935541805> ?p ?o ?g. }
- W2935541805 endingPage "648" @default.
- W2935541805 startingPage "636" @default.
- W2935541805 abstract "Background Late-line treatment options for patients with ovarian cancer are few, with the proportion of patients achieving an overall response typically less than 10%, and median overall survival after third-line therapy of 5–9 months. In this study (QUADRA), we investigated the activity of niraparib monotherapy as the fourth or later line of therapy. Methods QUADRA was a multicentre, open-label, single-arm, phase 2 study that evaluated the safety and activity of niraparib in adult patients (≥18 years) with relapsed, high-grade serous (grade 2 or 3) epithelial ovarian, fallopian tube, or primary peritoneal cancer who had been treated with three or more previous chemotherapy regimens. The study was done in the USA and Canada, and 56 sites screened patients (50 sites treated at least one patient). Patients received oral niraparib 300 mg once daily continuously, beginning on day 1 and every cycle (28 days) thereafter until disease progression. The primary objective was the proportion of patients achieving an investigator-assessed confirmed overall response in patients with homologous recombination deficiency (HRD)-positive tumours (including patients with BRCA and without BRCA mutations) sensitive to their last platinum-based therapy who had received three or four previous anticancer therapy regimens (primary efficacy population). Efficacy analyses were additionally done in all dosed patients with measurable disease at baseline. Findings Between April 1, 2015 and Nov 1, 2017, we screened 729 patients for eligibility and enrolled 463 patients, who were initiated on niraparib therapy. At the time of database lock (April 11, 2018), enrolment had closed and the study was ongoing, with 21 patients still on treatment. Patients had received a median of four (IQR 3–5) previous lines of therapy, and the median follow-up for overall survival was 12·2 months (IQR 3·7–22·1). 151 (33%) of 463 patients were resistant and 161 (35%) of 463 patients were refractory to the last administered platinum therapy. 13 (28%) of 47 patients in the primary efficacy population achieved an overall response according to RECIST (95% CI 15·6–42·6; one-sided p=0·00053). The most common drug-related grade 3 or worse treatment-emergent adverse events were anaemia (113 [24%] of 463 patients) and thrombocytopenia (95 [21%] of 463 patients). The most common treatment-emergent serious adverse events were small intestinal obstruction (34 [7%] of 463 patients), thrombocytopenia (34 [7%] of 463 patients), and vomiting (27 [6%] of 463 patients). One death due to gastric haemorrhage was considered treatment related. Interpretation We observed clinically relevant activity of niraparib among women with heavily pretreated ovarian cancer, especially in patients with HRD-positive platinum-sensitive disease, which includes not only patients with a BRCA mutation but also a population with BRCA wild-type disease. We identified no new safety signals. Our data support expansion of the treatment indication for poly(ADP-ribose) polymerase inhibitors to include patients with HRD-positive ovarian cancer beyond those with BRCA mutations. Funding Tesaro." @default.
- W2935541805 created "2019-04-11" @default.
- W2935541805 creator A5000603863 @default.
- W2935541805 creator A5014611244 @default.
- W2935541805 creator A5016505594 @default.
- W2935541805 creator A5018001559 @default.
- W2935541805 creator A5023214008 @default.
- W2935541805 creator A5024129361 @default.
- W2935541805 creator A5031844208 @default.
- W2935541805 creator A5032408469 @default.
- W2935541805 creator A5032849063 @default.
- W2935541805 creator A5033923828 @default.
- W2935541805 creator A5037590677 @default.
- W2935541805 creator A5046031005 @default.
- W2935541805 creator A5046159625 @default.
- W2935541805 creator A5058249824 @default.
- W2935541805 creator A5062151371 @default.
- W2935541805 creator A5063723398 @default.
- W2935541805 creator A5066909949 @default.
- W2935541805 creator A5068144319 @default.
- W2935541805 creator A5069337573 @default.
- W2935541805 creator A5084800083 @default.
- W2935541805 date "2019-05-01" @default.
- W2935541805 modified "2023-10-16" @default.
- W2935541805 title "Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial" @default.
- W2935541805 cites W1964064617 @default.
- W2935541805 cites W1973268287 @default.
- W2935541805 cites W1983817271 @default.
- W2935541805 cites W1992471607 @default.
- W2935541805 cites W2043178214 @default.
- W2935541805 cites W2054165449 @default.
- W2935541805 cites W2094049066 @default.
- W2935541805 cites W2118548073 @default.
- W2935541805 cites W2122763619 @default.
- W2935541805 cites W2128746885 @default.
- W2935541805 cites W2133296598 @default.
- W2935541805 cites W2135409663 @default.
- W2935541805 cites W2156077962 @default.
- W2935541805 cites W2163468601 @default.
- W2935541805 cites W2171658624 @default.
- W2935541805 cites W2171972386 @default.
- W2935541805 cites W2326304879 @default.
- W2935541805 cites W2335929230 @default.
- W2935541805 cites W2528228811 @default.
- W2935541805 cites W2587099744 @default.
- W2935541805 cites W2740934820 @default.
- W2935541805 cites W2751912349 @default.
- W2935541805 cites W2781525129 @default.
- W2935541805 cites W2782931979 @default.
- W2935541805 cites W2786086629 @default.
- W2935541805 cites W2804717005 @default.
- W2935541805 cites W2884001607 @default.
- W2935541805 cites W2891710662 @default.
- W2935541805 cites W2903876972 @default.
- W2935541805 doi "https://doi.org/10.1016/s1470-2045(19)30029-4" @default.
- W2935541805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30948273" @default.
- W2935541805 hasPublicationYear "2019" @default.
- W2935541805 type Work @default.
- W2935541805 sameAs 2935541805 @default.
- W2935541805 citedByCount "329" @default.
- W2935541805 countsByYear W29355418052019 @default.
- W2935541805 countsByYear W29355418052020 @default.
- W2935541805 countsByYear W29355418052021 @default.
- W2935541805 countsByYear W29355418052022 @default.
- W2935541805 countsByYear W29355418052023 @default.
- W2935541805 crossrefType "journal-article" @default.
- W2935541805 hasAuthorship W2935541805A5000603863 @default.
- W2935541805 hasAuthorship W2935541805A5014611244 @default.
- W2935541805 hasAuthorship W2935541805A5016505594 @default.
- W2935541805 hasAuthorship W2935541805A5018001559 @default.
- W2935541805 hasAuthorship W2935541805A5023214008 @default.
- W2935541805 hasAuthorship W2935541805A5024129361 @default.
- W2935541805 hasAuthorship W2935541805A5031844208 @default.
- W2935541805 hasAuthorship W2935541805A5032408469 @default.
- W2935541805 hasAuthorship W2935541805A5032849063 @default.
- W2935541805 hasAuthorship W2935541805A5033923828 @default.
- W2935541805 hasAuthorship W2935541805A5037590677 @default.
- W2935541805 hasAuthorship W2935541805A5046031005 @default.
- W2935541805 hasAuthorship W2935541805A5046159625 @default.
- W2935541805 hasAuthorship W2935541805A5058249824 @default.
- W2935541805 hasAuthorship W2935541805A5062151371 @default.
- W2935541805 hasAuthorship W2935541805A5063723398 @default.
- W2935541805 hasAuthorship W2935541805A5066909949 @default.
- W2935541805 hasAuthorship W2935541805A5068144319 @default.
- W2935541805 hasAuthorship W2935541805A5069337573 @default.
- W2935541805 hasAuthorship W2935541805A5084800083 @default.
- W2935541805 hasConcept C121608353 @default.
- W2935541805 hasConcept C126322002 @default.
- W2935541805 hasConcept C141071460 @default.
- W2935541805 hasConcept C143998085 @default.
- W2935541805 hasConcept C2776694085 @default.
- W2935541805 hasConcept C2776999253 @default.
- W2935541805 hasConcept C2778239845 @default.
- W2935541805 hasConcept C2778822529 @default.
- W2935541805 hasConcept C2780194787 @default.
- W2935541805 hasConcept C2780427987 @default.
- W2935541805 hasConcept C2780739268 @default.
- W2935541805 hasConcept C2781451048 @default.